Definition and validation of the Design Space for co-milled nasal powder containing nanosized lamotrigine

P. Gieszinger, I. Tomuta, T. Casian, Cs Bartos, P. Szabó-Révész, R. Ambrus

Research output: Article

Abstract

Objective: Design of Experiment (DoE), that is a tool of Quality by Design (QbD) paradigm, with which experiments can be planned more effectively and provide more information, while after Design Space (DS) can be set up, which assure the quality of the desired product. The aim of this study was to find the optimal drug-excipient ratio and the optimal process parameters (milling time, milling speed) of our previously used dry co-milling method and validate the DS. Materials and methods: Lamotrigine (LAM), an antiepileptic drug was used as a model API. Poly-vinyl alcohol (PVA) was chosen according to our previous study as a hydrophylic matrix polymer. Milling time, speed, and the API:additive ratio was varied to find out their effect on the product. The optimization was performed on particle size of LAM, its standard deviation and the in vitro dissolution of the samples. Response surface modeling completed the statistical analysis that assessed the effects of independent variables on the responses. Results: Due to the DS estimation, a more economical sample preparation method was set up. Finally, the sample that was prepared according to the optimized parameters (1.5 h, 400 rpm, 0.8 PVA:LAM ratio) showed around 100 nm drug particles and 97% drug release in five minutes. Conclusion: From the DS generated by the software, an optimal formulation was obtained and the results validated the experimental design. The QbD approach was a useful and effective tool of understanding the parameters that affect the quality of the desired product.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalDrug Development and Industrial Pharmacy
DOIs
Publication statusAccepted/In press - jún. 29 2018

Fingerprint

Nose
Powders
Alcohols
Excipients
Application programming interfaces (API)
Particle Size
Pharmaceutical Preparations
Anticonvulsants
Design of experiments
Polymers
Research Design
Software
Polymer matrix
lamotrigine
Statistical methods
Dissolution
Particle size
Experiments

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Definition and validation of the Design Space for co-milled nasal powder containing nanosized lamotrigine. / Gieszinger, P.; Tomuta, I.; Casian, T.; Bartos, Cs; Szabó-Révész, P.; Ambrus, R.

In: Drug Development and Industrial Pharmacy, 29.06.2018, p. 1-9.

Research output: Article

@article{d5d3162f286b469e98e1f0be80c2d31e,
title = "Definition and validation of the Design Space for co-milled nasal powder containing nanosized lamotrigine",
abstract = "Objective: Design of Experiment (DoE), that is a tool of Quality by Design (QbD) paradigm, with which experiments can be planned more effectively and provide more information, while after Design Space (DS) can be set up, which assure the quality of the desired product. The aim of this study was to find the optimal drug-excipient ratio and the optimal process parameters (milling time, milling speed) of our previously used dry co-milling method and validate the DS. Materials and methods: Lamotrigine (LAM), an antiepileptic drug was used as a model API. Poly-vinyl alcohol (PVA) was chosen according to our previous study as a hydrophylic matrix polymer. Milling time, speed, and the API:additive ratio was varied to find out their effect on the product. The optimization was performed on particle size of LAM, its standard deviation and the in vitro dissolution of the samples. Response surface modeling completed the statistical analysis that assessed the effects of independent variables on the responses. Results: Due to the DS estimation, a more economical sample preparation method was set up. Finally, the sample that was prepared according to the optimized parameters (1.5 h, 400 rpm, 0.8 PVA:LAM ratio) showed around 100 nm drug particles and 97{\%} drug release in five minutes. Conclusion: From the DS generated by the software, an optimal formulation was obtained and the results validated the experimental design. The QbD approach was a useful and effective tool of understanding the parameters that affect the quality of the desired product.",
keywords = "Design Space, dry milling, lamotrigine, nanoparticle, nasal powder",
author = "P. Gieszinger and I. Tomuta and T. Casian and Cs Bartos and P. Szab{\'o}-R{\'e}v{\'e}sz and R. Ambrus",
year = "2018",
month = "6",
day = "29",
doi = "10.1080/03639045.2018.1483388",
language = "English",
pages = "1--9",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Definition and validation of the Design Space for co-milled nasal powder containing nanosized lamotrigine

AU - Gieszinger, P.

AU - Tomuta, I.

AU - Casian, T.

AU - Bartos, Cs

AU - Szabó-Révész, P.

AU - Ambrus, R.

PY - 2018/6/29

Y1 - 2018/6/29

N2 - Objective: Design of Experiment (DoE), that is a tool of Quality by Design (QbD) paradigm, with which experiments can be planned more effectively and provide more information, while after Design Space (DS) can be set up, which assure the quality of the desired product. The aim of this study was to find the optimal drug-excipient ratio and the optimal process parameters (milling time, milling speed) of our previously used dry co-milling method and validate the DS. Materials and methods: Lamotrigine (LAM), an antiepileptic drug was used as a model API. Poly-vinyl alcohol (PVA) was chosen according to our previous study as a hydrophylic matrix polymer. Milling time, speed, and the API:additive ratio was varied to find out their effect on the product. The optimization was performed on particle size of LAM, its standard deviation and the in vitro dissolution of the samples. Response surface modeling completed the statistical analysis that assessed the effects of independent variables on the responses. Results: Due to the DS estimation, a more economical sample preparation method was set up. Finally, the sample that was prepared according to the optimized parameters (1.5 h, 400 rpm, 0.8 PVA:LAM ratio) showed around 100 nm drug particles and 97% drug release in five minutes. Conclusion: From the DS generated by the software, an optimal formulation was obtained and the results validated the experimental design. The QbD approach was a useful and effective tool of understanding the parameters that affect the quality of the desired product.

AB - Objective: Design of Experiment (DoE), that is a tool of Quality by Design (QbD) paradigm, with which experiments can be planned more effectively and provide more information, while after Design Space (DS) can be set up, which assure the quality of the desired product. The aim of this study was to find the optimal drug-excipient ratio and the optimal process parameters (milling time, milling speed) of our previously used dry co-milling method and validate the DS. Materials and methods: Lamotrigine (LAM), an antiepileptic drug was used as a model API. Poly-vinyl alcohol (PVA) was chosen according to our previous study as a hydrophylic matrix polymer. Milling time, speed, and the API:additive ratio was varied to find out their effect on the product. The optimization was performed on particle size of LAM, its standard deviation and the in vitro dissolution of the samples. Response surface modeling completed the statistical analysis that assessed the effects of independent variables on the responses. Results: Due to the DS estimation, a more economical sample preparation method was set up. Finally, the sample that was prepared according to the optimized parameters (1.5 h, 400 rpm, 0.8 PVA:LAM ratio) showed around 100 nm drug particles and 97% drug release in five minutes. Conclusion: From the DS generated by the software, an optimal formulation was obtained and the results validated the experimental design. The QbD approach was a useful and effective tool of understanding the parameters that affect the quality of the desired product.

KW - Design Space

KW - dry milling

KW - lamotrigine

KW - nanoparticle

KW - nasal powder

UR - http://www.scopus.com/inward/record.url?scp=85049555505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049555505&partnerID=8YFLogxK

U2 - 10.1080/03639045.2018.1483388

DO - 10.1080/03639045.2018.1483388

M3 - Article

C2 - 29863907

AN - SCOPUS:85049555505

SP - 1

EP - 9

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

ER -